The European Union approves the marketing of everuximab, expanding the scope of treatment

Recently, the European Commission (EC) officially approved Evinacumab (Evinacumab, trade name: Evkeeza) to expand its treatment scope and bring this innovative drug to more patients in need. This approval not only reflects the European Union's recognition of the efficacy and safety of everumab, but also further enriches the treatment options for patients with homozygous familial hypercholesterolemia (HoFH).

Ivezumab is a fully human anti-ANGPTL3 (angiopoietin-like protein3) monoclonal antibody that blocks ANGPTL3 effectively inhibits the activity of lipoprotein lipase and liver lipase, thereby reducing the accumulation of triglycerides and cholesterol in plasma and reducing LDL-C (low-density lipoprotein cholesterol) levels. This unique mechanism of action allows evisumumab to exhibit significant efficacy in the treatment of HoFH.

The EU's approval expands the therapeutic scope of Ivesumumab, further reducing the applicable age to HoFH pediatric patients from 6 months to 5 years old. Ivezumab has previously been approved in the EU for the treatment of HoFH patients aged 12 years and above, and pediatric patients aged 5 to 11 years. This expansion makes everevuzumab the first and only drug in the EU for pediatric patients aged 6 months to 5 years old with HoFH, bringing new treatment hope to these young patients.

HoFH is a rare and serious hereditary disease. Patients have severe impairment or loss of LDL receptor function due to LDL receptor gene mutations, resulting in abnormally elevated levels of LDL-C in the blood. Without effective treatment, patients face a significant risk of early cardiovascular disease and premature death. The launch of everuximab provides a new treatment method for HoFH patients, helping to reduce the risk ofLDL-C levels, reducing the risk of cardiovascular disease.

Reference materials:https://www.drugs.com/mtm/evinacumab.html

xa0